The new dosing regimen of Pennsaid will be 50 drops per knee, three times a day, as an alternative to the existing approved dosing regimen of 40 drops per knee, four times a day. According to the company, Pennsaid is now the only topical NSAID approved in Canada with this new improved dosing regimen.
Henrich Guntermann, Nuvo’s president and CEO, said: “The new improved dosing regimen of Pennsaid is a significant clinical advantage. We are eager to replicate Pennsaid’s Canadian success in the US market and continue to work diligently on obtaining FDA approval.”